Skip Navigation LinksHome > September 2008 - Volume 51 - Issue 3 > Breast Cancer and Hormonal Therapy
Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e318180b8ed
Evidence-Based Approach to Menopause

Breast Cancer and Hormonal Therapy

CONNER, PETER MD, PhD; LUNDSTRÖM, EVA MD, PhD; VON SCHOULTZ, BO MD, PhD

Collapse Box

Abstract

Valid evidence from randomized-controlled trials indicates that breast cancer risk is increased with combined estrogen/progestogen use and that such treatment implies a risk greater than that of estrogen alone. Overall, risk estimates from observational studies are somewhat higher than in randomized-controlled trials but remain modest as compared with other risk factors even after long-term treatment. For combined estrogen/progestogen therapy, risk increases gradually to reach statistical significance after 4 to 5 years. Apart from its many beneficial health effects, the safety data for use of estrogen alone are quite reassuring. The only justifications for progestogen addition are for bleeding control and endometrial protection. At present, there are several new therapeutic compounds and concepts in development, which hold promise to provide both endometrial protection and breast safety.

© 2008 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.